welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Annemieke Aartsma-Rus, PhD
Department of Human Genetics
Leiden University Medical Center
Dr. Annemieke Aartsma-Rus played an important role in the development of the antisense mediated exon skipping therapy for Duchenne muscular dystrophy during her PhD research (2000–2004) at the Leiden University Medical Center, Department of Human Genetics (the Netherlands). Since September 2004 she continued this research as a post doc. As of December 2007 she became leader of the “DMD exon skip group” first, as assistant professor and currently full professor at the Department of Human Genetics. Since 2013 she has a visiting professorship at the Institute of Genetic Medicine of Newcastle University (UK).
Her work currently focuses on developing antisense-mediated exon skipping as a therapy for Duchenne muscular dystrophy. This involves work in cell and animal models to improve delivery and efficiency of exon skipping compounds, studies in muscle regeneration and pathology, the identification of biomarkers, studying the basics of pre-mRNA splicing and transcript processing and the generation of mouse models. In addition, in collaborative efforts she aims to develop the exon skipping approach as a therapeutic option for other rare diseases and to bridge the gap between different stakeholders (patients, academics, regulators and industry) involved in drug development for rare diseases.
In 2017 she was elected as President Elect for the Oligonucleotide Therapeutics Society. In 2013 she was elected a member of the junior section of the Dutch Royal Academy of Sciences, which consists of what are considered the top 50 scientists in the Netherlands under 45. In 2015, 2016 and 2017 she was selected as most influential scientist in Duchenne muscular dystrophy in the past 10 years by Expertscape based on contributions to the understanding and treatment of Duchenne muscular dystrophy. In 2014 the Dutch lifestyle magazine selected her as one of the 400 most inspiring Dutch women; she was voted into the top 5 for ‘brainiacs’ by the general public.
Thus far, she has published over 150 peer-reviewed papers and 9 book chapters, as well as 15 patents and has edited one book. She has given many invited lectures at meetings, symposiums and workshops as well as patient/parent organizations meetings, where she is known for her ability to present science in a clear and understandable way. She has created and maintains multiple websites on therapeutic approaches for aimed at patients and parents. In 2011 she received the Duchenne Award from the Dutch Duchenne Parent Project in recognition of this work and her dedication to the Duchenne field. She also writes regular blogs for the LUMC.
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular DystrophyThis is a Phase 1, double-blind, placebo...
AAV9 U7snRNA Gene Therapy to Treat Boys With DMD Exon 2 DuplicationsOpen-label, single dose clinical trial o...
ICER Document Reviews Effectiveness of 3 Duchenne MD TherapiesThe Institute for Clinical and Economic ...
Antisense Oligonucleotides for the Treatment of Cardiomyopathy in Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is an ...
FDA paves way for clinical trials of Sarepta’s Duchenne MD therapy SRP-5051The U.S. Food and Drug Administration ha...
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular DystrophyThis is an open-label study to assess th...
Open Label Study of GSK2402968 in Subjects With Duchenne Muscular DystrophyThe purpose of this study is to explore ...
Results at 96 Weeks of a Phase IIb Extension Study of the Exon-Skipping Drug Eteplirsen in Patients with Duchenne Mu...Objective: The objective of this study ...
Barry J. Byrne, MD, PhDDr. Barry J. Byrne is a clinician scient...